Chemycal has been acquired by 3E

Learn More

Upcoming Regulatory Discussions on Cosmetic Ingredients and Safety at the 7th Plenary Meeting


Your substances

None

This news contains references also to other Substances



The 7th plenary meeting is set to address a variety of significant topics concerning cosmetics regulation and safety, with a strong focus on new and draft mandates for certain chemicals and ingredients used in cosmetic products. Among the items for discussion are the evaluation and potential regulation of three specific chemical compounds: Ethyl Tafluprostamide (DDDE), Methylamido-Dihydro-Noralfaprostal (MDN), and Isopropyl Cloprostenate (IPCP), all of which are utilized in cosmetics. These substances are under scrutiny for their safety profiles and regulatory compliance.

Additionally, the exposure of children to Salicylic acid and Butylparaben is on the agenda, highlighting the ongoing concern over the safety of cosmetic ingredients for vulnerable populations. Two colorants, HC Red 18 and HC Yellow 16, are also up for review in their second submission phase, indicating a continued effort to evaluate the safety of cosmetic color additives.

The meeting will further delve into the Scientific Committee on Consumer Safety's (SCCS) responses to comments on previous opinions, particularly regarding Aluminium and Benzophenone-4. These discussions are crucial as they reflect the SCCS's stance on the safety of these widely used cosmetic ingredients and may influence future regulatory actions.

Draft opinions on several other ingredients, including Triphenylphosphate, Micro Silver, and Citral, are set for discussion and potential adoption. This stage is vital for determining the safety and regulatory status of these compounds in cosmetics. Moreover, the evaluation of nanomaterials, specifically three coatings for Titanium Dioxide (TiO2) nano-particles and Hydroxyapatite (HAP) in its fourth submission phase, underscores the increasing attention on the safety of nanomaterials in cosmetic products.

MORE INFO ON: health.ec.europa.eu

                   

Related News

Loading...